Integrative Hormone Optimization and Chiropractic Protocols

Integrative Hormone Optimization and Chiropractic Care: A Patient-Centered, Evidence-Based Pathway for Mood, Sleep, Libido, and Metabolic Health

Abstract

As Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, I guide you through a clear, first-person journey of modern, evidence-based hormone optimization and integrative chiropractic care. We will explore how declines in testosterone, estrogen, and progesterone affect mood, sleep, libido, and metabolism in all individuals; why delivery methods (pellets, injections, patches, creams/gels, and rapid-dissolve tablets) behave differently; and how to personalize dosing using physiology, symptoms, and lab trends. I will explain the intertwined roles of the hypothalamic-pituitary-gonadal (HPG) and hypothalamic-pituitary-adrenal (HPA) axes; highlight actionable protocols for perimenopause and postmenopause; discuss clomiphene and testosterone strategies in men; and show how integrative chiropractic care stabilizes autonomic tone, reduces pain, and improves exercise tolerance, thereby amplifying hormonal benefits.

Introduction: Why Hormones, Mood, Sleep, and Energy Collide

Every week in my clinic, I hear the same pattern:

• “I feel off—depressed, anxious, irritable.”
• “I wake between 2:00 and 4:00 AM and can’t get back to sleep.”
• “My focus crashes mid-afternoon.”
• “My libido is gone.”
• “I’m gaining weight and can’t lose it.”

These experiences are not “all in your head.” They reflect the interplay among the HPG axis, HPA axis, neurotransmitters, circadian biology, and metabolic networks. Declines in testosterone and estrogen reduce stabilizing signals to brain circuits that govern mood, reward, and sleep. Stress-related changes in cortisol further fragment sleep, drive early-morning awakenings, and impair slow-wave and REM sleep, disrupting memory consolidation and emotional regulation (Meerlo et al., 2008; Walker, 2017). Clinically, when we restore hormonal balance while recalibrating sleep timing and autonomic tone, symptoms improve in durable, measurable ways.

Hormone-Driven Mood and Sleep: The Physiology Behind Symptoms

The intersection of hormones and sleep explains much of what patients feel:

• The HPG axis (hypothalamus → pituitary → gonads) regulates estradiol and testosterone. Declines reduce positive feedback on neuronal circuits that maintain mood stability and sleep continuity (Amin et al., 2005; Andersen & Tufik, 2003).
• The HPA axis controls cortisol’s circadian rhythm. Low sex steroids often push autonomic tone toward sympathetic overdrive, creating erratic nocturnal cortisol pulses that fragment sleep and trigger early awakenings (Meerlo et al., 2008; Walker, 2017).
• Estrogen modulates serotonergic and GABAergic signaling, supporting calm mood and consolidated sleep. When estrogen drops, irritability, anxiety, and insomnia often rise (Amin et al., 2005).
• Testosterone supports dopaminergic motivation and influences sleep architecture; low levels correlate with anhedonia, reduced vitality, and mid-day energy “walls” (Andersen & Tufik, 2003; Wu et al., 2010).

In my practice, patients who experience a mid-afternoon slump often exhibit low free testosterone, fluctuating estradiol levels, and indications of sleep deprivation. Correcting these imbalances while rebuilding sleep structure results in meaningful improvements in mood, focus, and energy.

Loss of Enjoyment, Libido, and Metabolic Changes: Hallmarks of Hormonal Decline

Men often report the loss of morning erections and decreased drive; women describe low libido, dryness, and reduced interest. In men, testosterone insufficiency is a central driver of erectile quality, motivation, and exercise capacity. In women, low testosterone reduces desire and energy, while estrogen decline contributes to genitourinary syndrome of menopause (GSM) and dyspareunia, further suppressing libido (Kingsberg et al., 2019).

Metabolically, sex steroid deficiency reduces mitochondrial biogenesis and promotes sarcopenia. Low testosterone increases fat mass and decreases insulin sensitivity in men; loss of estrogen drives central adiposity and adverse lipid shifts in women (Kelly & Jones, 2013; Pinkerton, 2020). Patients may experience night sweats, fibromyalgia-like pain, and fatigue—symptoms linked to autonomic imbalance and inflammatory signaling intertwined with hormonal decline.

Men’s Fertility and Clomiphene: Who Benefits and Why It Fades With Age

For younger men who want to preserve fertility, clomiphene citrate (a selective estrogen receptor modulator) can raise endogenous testosterone by blocking estrogen’s negative feedback at the hypothalamus, increasing GnRH, LH, and FSH. Younger patients with healthy pituitary function respond best. As men get older, LH signaling gets weaker, and clomiphene doesn’t always help much. For many men in their 40s and 50s, direct testosterone replacement therapy is more effective (Taylor & Levine, 2010; Patel et al., 2019). In my clinic, I reserve clomiphene for younger men seeking fertility who demonstrate robust gonadotropin responsiveness; otherwise, I favor predictable replacement methods.

Choosing the Right Route: Pellets, Patches, Creams/Gels, Injections, and Rapid-Dissolve Tablets

Understanding pharmacokinetics helps match therapy to physiology and lifestyle.

Pellets: Continuous Delivery and Practical Nuances

Pellet therapy offers steady-state exposure over approximately 3–5 months. Patients often appreciate:

• Stable mood and sleep without peaks/troughs
• Improved libido and energy with fewer dose fluctuations
• Convenience and adherence

However, pellets are not easily removed once placed. Over decades, I have not needed to remove a pellet; nuisance side effects typically fade as pellets wear off. Not all pellets perform identically—variations in compression, softness, and excipients affect dissolution. Subcutaneous placement into fatty tissue supports sustained release. Sensitive patients, especially women, may notice unwanted hair growth at androgen-responsive sites due to local 5-alpha reductase activity (Mulligan et al., 2006). We individualize dosing based on age, time since menopause/andropause, symptom severity, and lab trends, and we educate patients about non-removability before placement.

Transdermal Creams and Gels: Flexibility With Caveats

Transdermal testosterone and estradiol offer flexible titration, but absorption varies. Testosterone cream can cause local hair growth at the site of application, particularly in thin or vascular skin. Alcohol-based commercial gels may irritate the genital application sites; non-genital applications (neck or shoulders) may modestly improve absorption.

Key considerations:

• Timing labs after creams/gels can yield spuriously high serum values; avoid drawing shortly after application.
• For women, vaginal estradiol improves local tissue elasticity and lubrication but typically does not reach systemic levels sufficient to resolve all menopausal symptoms (North American Menopause Society, 2023).
• For women with oncology constraints, local therapies are tailored under multidisciplinary oversight.

Estradiol Patches: Reliable Pharmacokinetics and Accessibility

Patches provide predictable dosing with steady serum levels and are often covered by insurance. I typically start at a mid-range dose for symptomatic women, especially when very low doses fail. Dose adjustments consider skin tone/thickness, symptom response, and lab trends. In postmenopausal women with a uterus, systemic estrogen always requires micronized progesterone for endometrial protection (North American Menopause Society, 2023).

Injections: Precision With Peak-Trough Dynamics

Injections deliver precise amounts but can produce peaks and troughs, amplifying side effects—particularly in women. High or infrequent testosterone injections in women can drive voice changes, temporal balding, and acne due to supraphysiologic peaks. In men, weekly or twice-weekly testosterone cypionate is standard; typical starting ranges are approximately 100–200 mg per week, titrated to age, metabolism, and clinical response. Splitting doses can reduce peaks and side effects (Corona et al., 2021).

Pharmacologic pearls:

• Testosterone cypionate is labeled for intramuscular administration; subcutaneous administration can cause localized nodules unless properly dispersed and massaged.
• Many commercial pharmacies will not dispense subcutaneous low-dose testosterone formulations for women due to labeling constraints; compounded options are often necessary.
• For women, fractional microdoses (e.g., 2–5 mg daily subcutaneous) or rapid-dissolve tablets (RDTs) can minimize peak levels while maintaining symptom control.

Oral and Rapid-Dissolve Options: First-Pass Metabolism Considerations

Oral estradiol undergoes first-pass hepatic metabolism, increasing certain metabolites and clotting factors; transdermal routes reduce thrombotic risk in higher-risk contexts (Canonico et al., 2016; North American Menopause Society, 2023). Sublingual RDTs/troches bypass first-pass metabolism. In my practice:

• Estradiol RDTs provide rapid relief of vasomotor symptoms; I titrate based on symptom response and time labs away from peaks.
• Testosterone RDTs can be effective at low milligram ranges in women; high-dose RDTs are impractical for men due to size and cost.
• Troches dissolve slowly and often taste unpleasant; many patients swallow them, negating the absorption benefit. RDTs typically perform better.

Progressive Monitoring: Avoiding Data Pitfalls

To avoid misleading data:

• Do not draw labs shortly after cream/gel application.
• Time RDT monitoring approximately 3–4 hours post-dose to estimate peaks.
• Prioritize validated symptom scores and interval lab trends over isolated numbers.

Progesterone: The Calming Hormone and Endometrial Protection

Progesterone is a GABAergic modulator that improves sleep and reduces irritability. In perimenopause, progesterone declines often precede major estrogen drops, which is why women in their 40s may experience mood swings, anxiety, insomnia, and heavy periods despite normal estradiol. Postmenopausal women receiving systemic estrogen require 200 mg oral micronized progesterone to protect the endometrium; transdermal progesterone creams are inadequate for uterine safety (North American Menopause Society, 2023).

Clinical pearls from my practice:

• If oral progesterone causes excessive somnolence or breast tenderness, I may use sublingual dosing or combine a reduced oral dose with a small sublingual component.
• In older women (>70 years) or those far (>20 years) from menopause, receptors can be dormant; start low and go slow to avoid breast pain, spotting, or nausea.

Time Since Menopause: Receptor Dormancy and Dosing Strategy

Two women with similar lab results may respond differently due to receptor dormancy. A 52-year-old at 2–4 years post-menopause usually tolerates standard dosing; a 72-year-old at 22 years post-menopause may react strongly to the same dose. I therefore:

• Start at lower, fractionated doses in older patients
• Use patches or low-dose RDTs for gentle titration
• Introduce progesterone early to support sleep and anxiolysis
• Reassess every 4–8 weeks, emphasizing symptom change and cautious titration

Perimenopause vs. Postmenopause: Treating Physiology, Not Just Labs

In perimenopause, estradiol swings drive vasomotor instability. Treating a patient who has had a menstrual period within the last 12 months as postmenopausal often results in mastalgia, edema, and heavy bleeding. A safer approach is very low-dose estradiol to smooth peaks and troughs and progesterone for sleep and uterine balance. Once 12 months of amenorrhea are confirmed, we titrate estradiol for durable relief and cardiometabolic benefits with appropriate endometrial protection (Canonico et al., 2016; North American Menopause Society, 2023).

FSH as a Mid-Term Compass

I follow follicle-stimulating hormone (FSH) as a mid-term indicator of central estrogen signaling. As estradiol signaling improves, FSH typically declines, often paralleling reductions in vasomotor symptoms and improvements in sleep, mood, and cognition. My practical goal is a progressive reduction over the course of months as therapy stabilizes (Burger et al., 2002; Freeman et al., 2014; Manson et al., 2013).

Testosterone in Women: Free Fraction, SHBG, and Function Over Numbers

Women’s androgen physiology is nuanced. There are no universal normal ranges for female testosterone. I use symptoms to guide care—low libido, fatigue, decreased motivation, cognitive dulling, and reduced strength—and prioritize free testosterone as the closest correlate of clinical response. Direct free testosterone assays outperform calculated methods (Rosner et al., 2007; Davis & Wahlin-Jacobsen, 2015). High SHBG (often induced by oral estrogen) blunts free fractions, sometimes necessitating a higher total dose to achieve adequate free signaling. Conversely, low SHBG means even small doses can produce high free levels, increasing the risk of acne or hair changes (Handelsman et al., 2016). We treat the patient, not just the lab, and correct hidden levers—thyroid, iron, inflammation, gut health—before escalating indefinitely.

Integrative Chiropractic Care: Aligning Structure, Autonomic Balance, and Hormonal Outcomes

Hormone therapy works best when the autonomic and musculoskeletal systems are stable. In my integrative clinic, chiropractic care supports hormone optimization by:

• Reducing nociceptive input from joint and soft-tissue dysfunction that perpetuates sympathetic overdrive and sleep fragmentation
• Restoring postural alignment and rib cage mechanics to improve breathing efficiency and nocturnal oxygenation—key for stable sleep architecture
• Enhancing proprioceptive feedback via spinal adjustments and soft tissue mobilization, helping normalize autonomic output and lower cortisol reactivity (Bialosky et al., 2009)
• Improving exercise tolerance so patients can re-engage with resistance training and aerobic movement—critical for insulin sensitivity, mitochondrial health, and androgen signaling

My clinical observations:

• Patients who combine structured chiropractic care with hormone therapy experience smoother mood improvements and quicker sleep consolidation, particularly those with cervicothoracic dysfunction contributing to nocturnal arousals.
• Women with GSM plus pelvic floor tension benefit from coordinated pelvic floor therapy and gentle sacral mobilization alongside local estrogen; dyspareunia decreases, and libido re-engages.
• Men with mid-day crashes often respond to thoracic mobility work and diaphragmatic training, lowering sympathetic tone and improving focus when combined with testosterone titration.

You can explore ongoing clinical insights and case discussions on WellnessDoctorRX and my professional updates on LinkedIn.

Functional Medicine Foundations: Thyroid, Iron, Inflammation, and Gut Health

When symptoms persist despite appropriate sex-steroid dosing, I evaluate:

• Thyroid function: TSH plus free T4 and free T3 for conversion issues; low ferritin impairs synthesis and utilization; autoimmunity (TPO/Tg antibodies) requires gut-immune support (Stanczyk et al., 2013).
• Iron indices: Iron and ferritin influence mitochondrial function and thyroid action; low ferritin contributes to fatigue, hair changes, and poor exercise tolerance.
• Inflammation: hs-CRP and clinical signs of chronic inflammatory load, often driven by visceral adiposity, sleep apnea, or gut dysbiosis.
• Gut integrity: The estrobolome modulates estrogen metabolism via enterohepatic recirculation; optimizing fiber intake, probiotics, and liver support can stabilize estrogenic signaling and reduce side effects (Baker et al., 2017; Kwa et al., 2016).

Layering therapies slowly clarifies causality, avoids confounding, and supports durable outcomes.

Men’s Hormone Care: Straighter Lines, Same Principles

Men’s protocols are often more straightforward. We assess symptoms, obtain total and free testosterone, monitor PSA, and consider estradiol when gynecomastia or mood lability appears. We restore testosterone to physiological ranges to relieve symptoms, manage estradiol levels rather than reflexively suppressing them, and always integrate chiropractic and lifestyle interventions to support sleep, recovery, and cardiometabolic health (Corona et al., 2014; AUA, 2018). Monitoring hematocrit is essential for men on injectables to mitigate the risk of erythrocytosis.

Practical Clinical Workflow: My Stepwise Model

• Baseline assessment: fasting labs (testosterone total/free, estradiol, SHBG, LH/FSH where indicated, DHEA-S, thyroid panel, CBC, CMP, A1c, fasting insulin/HOMA-IR, lipids, hs-CRP, vitamin D, ferritin/iron indices). For men, add PSA.
• Intake symptom scales: I use the Menopause Rating Scale and related tools to quantify vasomotor episodes, sleep quality, mood, and urogenital symptoms (Heinemann et al., 2004).
• Choose delivery route:
  • Women: estradiol patch or low-dose RDT; add oral micronized progesterone 200 mg nightly in postmenopause; consider local vaginal estradiol for GSM; add low-dose testosterone via daily micro-injections or RDT to address libido and vitality.
  • Men: weekly or split testosterone cypionate injections, patches/gels, or pellets for steady-state; consider clomiphene for younger men preserving fertility; manage estradiol and hematocrit proactively.
• Integrative care: chiropractic adjustments, myofascial release, postural correction, breathing mechanics, sleep hygiene, and structured resistance training.
• Monitoring and titration: validate symptom changes using scales, time labs for each delivery method, and titrate based on both functional and lab trends.
• Safety oversight: prostate health in men; endometrial safety in women; favor transdermal estrogen to mitigate thrombotic risk where appropriate; monitor hematocrit in men (AUA, 2018; North American Menopause Society, 2023).

Clinical Scenarios: How I Decide

• A 45-year-old woman with heavy clotting periods, anxiety, and 2:00–4:00 AM awakenings: I suspect luteal progesterone insufficiency. I start 100–200 mg micronized progesterone nightly, optimize sleep hygiene, and consider a low-dose estradiol patch if vasomotor symptoms are significant. Pelvic floor-friendly chiropractic alignment improves diaphragmatic mechanics and sleep recovery. Reassess in 6–8 weeks.
• A 54-year-old postmenopausal woman with low libido and mood swings: I initiate an estradiol patch plus 200 mg oral progesterone, then add low-dose testosterone via daily micro-injection or RDT with careful monitoring for hair changes or acne. Strength training, supported by chiropractic mobility and core integration, accelerates metabolic and mood improvements.
• A 38-year-old man wanting fertility: I trialed clomiphene with LH/FSH monitoring. If robust, we continue with lifestyle optimization. If LH signaling is weak, we pivot to low-dose injectables; pellets may be considered for steady-state.
• A 62-year-old man with afternoon crashes, low libido, and loss of morning erections: I start testosterone cypionate around 100–150 mg weekly, split dosing to reduce peaks. We monitor estradiol, hematocrit, and symptom response. I add thoracic mobility and diaphragmatic training; structured resistance exercise restores insulin sensitivity and vitality.

Why We Avoid Certain Approaches

• High-dose or infrequent testosterone injections in women: These amplify peak-driven adverse effects like voice changes and balding. Fractionated dosing or alternative routes are safer and more physiologic.
• Progesterone cream for endometrial protection: This is inadequate for postmenopausal women on systemic estrogen. We stick to oral micronized progesterone to meet safety standards (North American Menopause Society, 2023).
• Over-reliance on cream-based lab monitoring: Values shortly post-application can be misleadingly high; I prioritize appropriately timed labs and symptom trends.

Bringing It All Together: A Patient-Centered, Integrated Model

The strongest outcomes emerge when we align physiology with lived experience and integrate musculoskeletal care. Hormone therapy stabilizes the neuroendocrine terrain; chiropractic care reduces stress inputs and restores autonomic balance; movement, nutrition, and sleep hygiene consolidate gains. Across my work at WellnessDoctorRX and professional collaborations, patients do best when they receive a tailored combination of:

• Evidence-based hormone delivery at the right dose and cadence
• Endometrial and prostate safety monitoring
• Alignment, mobility, and breathing optimization
• Nutritional support emphasizing protein, fiber, and micronutrients
• Sleep structure and circadian alignment
• Stress modulation practices that reinforce parasympathetic tone

With this approach, patients who arrive exhausted and discouraged regain calm sleep, focused days, a restored libido, and steady energy—without the roller coaster.

---

References

• Amin, Z., Epperson, C. N., & Constable, R. T. (2005). Gender differences in the impact of sleep on mood. Neuroinformatics, 5(1), 17–26.
• American Urological Association. (2018). Testosterone deficiency: AUA guideline.
• Andersen, M. L., & Tufik, S. (2003). Relationship between testosterone and sleep: A review. Neuroscience & Biobehavioral Reviews, 27(6), 469–478.
• Baker, J. M., Al-Nakkash, L., & Herbst-Kralovetz, M. M. (2017). The estrobolome and its influence on estrogen metabolism. Frontiers in Endocrinology, 7, 25.
• Bialosky, J. E., Bishop, M. D., & George, S. Z. (2009). Spinal manipulative therapy-specific changes in pain sensitivity. The Journal of Pain, 10(9), 886–897.
• Burger, H. G., Dudley, E. C., Robertson, D. M., & Dennerstein, L. (2002). Perimenopause: The transition before menopause. The Journal of Clinical Endocrinology & Metabolism, 87(7), 3160–3167.
• Canonico, M., Fournier, A., & Scarabin, P.-Y. (2016). Transdermal versus oral estrogen and thrombotic risk. Climacteric, 19(4), 331–337.
• Corona, G., et al. (2014). Hypogonadism in males: Diagnosis and treatment. International Journal of Endocrinology, 2014, 1–15.
• Corona, G., et al. (2021). Functional outcomes of testosterone replacement therapy. The Journal of Clinical Endocrinology & Metabolism, 106(10), e4109–e4126.
• Davis, S. R., & Wahlin-Jacobsen, S. (2015). Testosterone in women: Clinical perspectives. The Journal of Clinical Endocrinology & Metabolism, 100(3), 812–824.
• Freeman, E. W., et al. (2014). Hormones and menopausal status on mood and hot flashes. Menopause, 21(8), 830–835.
• Handelsman, D. J., et al. (2016). Sex hormone-binding globulin and androgens: Clinical interpretation. The Journal of Clinical Endocrinology & Metabolism, 101(8), 3090–3099.
• Heinemann, L. A. J., et al. (2004). Menopause Rating Scale: A methodological review. Health and Quality of Life Outcomes, 2, 45.
• Kelly, D. M., & Jones, T. H. (2013). Testosterone and cardiometabolic health. Current Hypertension Reports, 15(4), 282–289.
• Kingsberg, S. A., et al. (2019). Vaginal estrogen for GSM: Evidence and recommendations. Menopause, 26(11), 1194–1203.
• Kwa, M., Plottel, C. S., Blaser, M. J., & Adams, S. (2016). The intestinal microbiome and estrogen metabolism. NPJ Breast Cancer, 2, 16005.
• Manson, J. E., et al. (2013). Menopausal hormone therapy and health outcomes. JAMA, 310(13), 1353–1368.
• Meerlo, P., Sgoifo, A., & Suchecki, D. (2008). Sleep deprivation and stress. Sleep Medicine Reviews, 12(2), 85–91.
• Mulligan, T., et al. (2006). Mechanisms of androgen action in hair follicles. The Journal of Clinical Endocrinology & Metabolism, 91(3), 976–984.
• North American Menopause Society. (2023). Hormone therapy position statement.
• Patel, A. S., et al. (2019). SERMs in male hypogonadism. Sexual Medicine Reviews, 7(2), 272–276.
• Pinkerton, J. V. (2020). Menopause management guidelines. Post Reproductive Health, 26(4), 181–209.
• Rosner, W., et al. (2007). Utility of free testosterone measurements. The Journal of Clinical Endocrinology & Metabolism, 92(2), 405–413.
• Taylor, F., & Levine, L. (2010). Clomiphene citrate for male hypogonadism. Urology, 75(4), 640–646.
• Walker, M. (2017). Why we sleep: Unlocking the power of sleep and dreams.
• Wu, F. C., et al. (2010). Hypogonadism in middle-aged men. The Journal of Clinical Endocrinology & Metabolism, 95(8), 3620–3629.